Infectious Complications of Dialysis Access Devices

Infectious Disease Clinics of North America

Volumn 26, Issue 1, 2012, Pages 127-141

  Bagdasarian, Natasha ^a   Heung, Michael ^b   Malani, Preeti N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Device infection; Dialysis; Renal disease

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CEPHALOSPORIN; CITRIC ACID; DAPTOMYCIN; GENTAMICIN; HEPARIN; MINOCYCLINE; PSEUDOMONIC ACID; RIFAMPICIN; SILVER; TAUROLIDINE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; BACTERIUM CONTAMINATION; CATHETER INFECTION; CATHETER REMOVAL; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIALYSIS CATHETER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TREATMENT FAILURE; EPIDEMIOLOGICAL DATA; HEMODIALYSIS; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY FAILURE; MATERIAL COATING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGY; NONHUMAN; PERITONEAL DIALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT PLANNING; VASCULAR ACCESS; VASCULAR PATENCY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; HUMANS; PERITONEAL DIALYSIS; RENAL DIALYSIS; RISK FACTORS; UNITED STATES;

EID: 84856264300     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.09.005     Document Type: Review

References (80)

1. US Renal Data System, USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the united states 2010, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).
2. Patel P.R., Kallen A.J., Arduino M.J. Epidemiology, surveillance, and prevention of bloodstream infections in hemodialysis patients. Am J Kidney Dis 2010, 56:566-577.
3. Gallieni M., Martini A., Mezzina N. Dialysis access: an increasingly important clinical issue. Int J Artif Organs 2009, 32:851-856.
4. Fitzgibbons L.N., Puls D.L., Mackay K., et al. Management of gram-positive coccal bacteremia and hemodialysis. Am J Kidney Dis 2011, 57:624-640.
5. James M.T., Laupland K.B., Tonelli M., et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med 2008, 168:2333-2339.
6. Hoen B., Paul-Dauphin A., Hestin D., et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. JAm Soc Nephrol 1998, 9:869-876.
7. Reddy S., Sullivan R., Zaiden R., et al. Hepatitis C infection and the risk of bacteremia in hemodialysis patients with tunneled vascular access catheters. South Med J 2009, 102:374-377.
8. Weijmer M.C., Vervloet M.G., ter Wee P.M. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant 2004, 19:670-677.
9. Taylor G., Gravel D., Johnston L., et al. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol 2002, 23:716-720.
10. Schild A.F., Perez E., Gillaspie E., et al. Arteriovenous fistulae vs. arteriovenous grafts: a retrospective review of 1,700 consecutive vascular access cases. JVasc Access 2008, 9:231-235.
11. Akoh J.A. Vascular access infections: epidemiology, diagnosis, and management. Curr Infect Dis Rep 2011, 13(4):324-332.
12. Yu Q., Yu H., Chen S., et al. Distribution and complications of native arteriovenous fistulas in maintenance hemodialysis patients: a single-center study. JNephrol 2011, 24(5):597-603.
13. Wish J.B. Vascular access for dialysis in the United States: progress, hurdles, controversies, and the future. Semin Dial 2010, 23:614-618.
14. Betjes M.G. Prevention of catheter-related bloodstream infection in patients on hemodialysis. Nat Rev Nephrol 2011, 7:257-265.
15. Ng L.J., Chen F., Pisoni R.L., et al. Hospitalization risks related to vascular access type among incident US hemodialysis patients. Nephrol Dial Transplant 2011, [Epub ahead of print].
16. Centers for Disease Control and Prevention (CDC) Vital signs: central line-associated blood stream infections-United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 2011, 60:243-248.
17. Ocak G., Halbesma N., le Cessie S., et al. Haemodialysis catheters increase mortality as compared to arteriovenous accesses especially in elderly patients. Nephrol Dial Transplant 2011, 26(8):2611-2617.
18. O'Grady N.P., Alexander M., Burns L.A., et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011, 52:e162-e193.
19. Kairaitis L.K., Gottlieb T. Outcome and complications of temporary haemodialysis catheters. Nephrol Dial Transplant 1999, 14:1710-1714.
20. Parienti J.J., Thirion M., Mégarbane B., et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 2008, 299:2413-2422.
21. Sychev D., Maya I.D., Allon M. Clinical management of dialysis catheter-related bacteremia with concurrent exit-site infection. Semin Dial 2011, 24:239-241.
22. Mermel L.A., Allon M., Bouza E., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
23. Nassar G.M., Ayus J.C. Infectious complications of the hemodialysis access. Kidney Int 2001, 60:1-13.
24. Saeed Abdulrahman I., Al-Mueilo S.H., Bokhary H.A., et al. prospective study of hemodialysis access-related bacterial infections. JInfect Chemother 2002, 8:242-246.
25. Safdar N., Maki D.G. The epidemiology of catheter-related infection in the critically ill. Catheter related infections in the critically ill 2004, 1-23. Kluwer, New York. N.P. O'Grady, D. Pittet (Eds.).
26. Mokrzycki M.H., Zhang M., Cohen H., et al. Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. Nephrol Dial Transplant 2006, 21:1024-1031.
27. Centers for Disease Control and Prevention (CDC) Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb Mortal Wkly Rep 2007, 56:197-199.
28. Montecalvo M.A., Shay D.K., Patel P., et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996, 156(13):1458-1462.
29. Servais A., Mercadal L., Brossier F., et al. Rapid curbing of a vancomycin-resistant Enterococcus faecium outbreak in a nephrology department. Clin J Am Soc Nephrol 2009, 4:1559-1564.
30. Naimi T.S., Anderson D., O'Boyle C., et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis 2003, 36:1609-1612.
31. Rice L.B. Antimicrobial resistance in gram-positive bacteria. Am J Med 2006, 119:S11-S19.
32. Chang S., Sievert D.M., Hageman J.C., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. NEngl J Med 2003, 348:1342-1347.
33. Pyrgos V., Ratanavanich K., Donegan N., et al. Candida bloodstream infections in hemodialysis recipients. Med Mycol 2009, 47:463-467.
34. Kamalakannan D., Pai R.M., Johnson L.B., et al. Epidemiology and clinical outcomes of infective endocarditis in hemodialysis patients. Ann Thorac Surg 2007, 83:2081-2086.
35. Marr K.A., Sexton D.J., Conlon P.J., et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997, 127:275-280.
36. Fowler V.G., Justice A., Moore C., et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005, 40:695-703.
37. Vandecasteele S.J., De Vriese A.S. Vancomycin dosing in patients on intermittent hemodialysis. Semin Dial 2011, 24:50-55.
38. Saad T.F. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999, 34:1114-1124.
39. Ashby D.R., Power A., Singh S., et al. Bacteremia associated with tunneled hemodialysis catheters: outcome after attempted salvage. Clin J Am Soc Nephrol 2009, 4:1601-1605.
40. Philipneri M., Al-Aly Z., Amin K., et al. Routine replacement of tunneled, cuffed, hemodialysis catheters eliminates paraspinal/vertebral infections in patients with catheter-associated bacteremia. Am J Nephrol 2003, 23:202-207.
41. Sychev D., Maya I.D., Allon M. Clinical outcomes of dialysis catheter-related candidemia in hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:1102-1105.
42. Chin B.S., Han S.H., Lee H.S., et al. Risk factors for recurrent catheter-related infections after catheter-related bloodstream infections. Int J Infect Dis 2010, 14:e16-e21.
43. Schutte W.P., Helmer S.D., Salazar L., et al. Surgical treatment of infected prosthetic dialysis arteriovenous grafts: total versus partial graft excision. Am J Surg 2007, 193:385-388.
44. Ryan S.V., Calligaro K.D., Scharff J., et al. Management of infected prosthetic dialysis arteriovenous grafts. JVasc Surg 2004, 39:73-78.
45. McCann M., Moore Z.E. Interventions for preventing infectious complications in haemodialysis patients with central venous catheters. Cochrane Database Syst Rev 2010, (1). CD006894.
46. Battistella M., Bhola C., Lok C.E. Long-term follow-up of the Hemodialysis Infection Prevention with Polysporin Ointment (HIPPO) Study: a quality improvement report. Am J Kidney Dis 2011, 57:432-441.
47. Chatzinikolaou I., Finkel K., Hanna H., et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med 2003, 115:352-357.
48. Trerotola S.O., Johnson M.S., Shah H., et al. Tunneled hemodialysis catheters: use of a silver-coated catheter for prevention of infection-a randomized study. Radiology 1998, 207:491-496.
49. Bambauer R., Mestres P., Schiel R., et al. Long-term catheters for apheresis and dialysis with surface treatment with infection resistance and low thrombogenicity. Ther Apher Dial 2003, 7:225-231.
50. Filiopoulos V., Hadjiyannakos D., Koutis I., et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. Am J Nephrol 2011, 33:260-268.
51. Maki D.G., Ash S.R., Winger R.K., et al. Anovel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med 2011, 39:613-620.
52. Kotsanas D., Polkinghorne K.R., Korman T.M., et al. Risk factors for peritoneal dialysis-related peritonitis: can we reduce the incidence and improve patient selection?. Nephrology (Carlton) 2007, 12:239-245.
53. Diaz-Buxo J.A., Himmele R. Strategies to universally improve peritonitis rates, including use of dialysis solutions with low glucose degradation products. Adv Perit Dial 2010, 26:37-40.
54. Zimmerman D.G. Presternal catheter design-an opportunity to capitalize on catheter immobilization. Adv Perit Dial 2010, 26:91-95.
55. Daly C.D., Campbell M.K., MacLeod A.M., et al. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol Dial Transplant 2001, 16:341-347.
56. Piraino B., Sheth H. Peritonitis-does peritoneal dialysis modality make a difference?. Blood Purif 2010, 29:145-149.
57. Li P.K., Szeto C.C., Piraino B., et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010, 30(4):393-423.
58. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003. Perit Dial Int 2009, 29:297-302.
59. Park S.J., Lee J.Y., Tak W.T., et al. Using reagent strips for rapid diagnosis of peritonitis in peritoneal dialysis patients. Adv Perit Dial 2005, 21:69-71.
60. Kofteridis D.P., Valachis A., Perakis K., et al. Peritoneal dialysis-associated peritonitis: clinical features and predictors of outcome. Int J Infect Dis 2010, 14:e489-e493.
61. Jarvis E.M., Hawley C.M., McDonald S.P., et al. Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. Kidney Int 2010, 78:408-414.
62. Fahim M., Hawley C.M., McDonald S.P., et al. Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. Am J Kidney Dis 2010, 55:690-697.
63. Restrepo C., Chacon J., Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. Perit Dial Int 2010, 30:619-625.
64. Miles R., Hawley C.M., McDonald S.P., et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int 2009, 76:622-628.
65. Bunke C.M., Brier M.E., Golper T.A. Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997, 52:524-529.
66. Bunke M., Brier M.E., Golper T.A. Pseudomonas peritonitis in peritoneal dialysis patients: the Network #9 Peritonitis Study. Am J Kidney Dis 1995, 25:769-774.
67. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus: glycopeptide-intermediate staphylococcus aureus Working Group. NEngl J Med 1999, 340:493-501.
68. Piraino B., Bailie G.R., Bernardini J., et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005, 25:107-131.
69. Wiggins K.J., Johnson D.W., Craig J.C., et al. Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis 2007, 50:967-988.
70. de Vin F., Rutherford P., Faict D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 2009, 29:5-15.
71. Chang T.I., Kim H.W., Park J.T., et al. Early catheter removal improves patient survival in peritoneal dialysis patients with fungal peritonitis: results of ninety-four episodes of fungal peritonitis at a single center. Perit Dial Int 2011, 31:60-66.
72. Posthuma N., Borgstein P.J., Eijsbouts Q., et al. Simultaneous peritoneal dialysis catheter insertion and removal in catheter-related infections without interruption of peritoneal dialysis. Nephrol Dial Transplant 1998, 13:700-703.
73. Cancarini G.C., Manili L., Brunori G., et al. Simultaneous catheter replacement-removal during infectious complications in peritoneal dialysis. Adv Perit Dial 1994, 10:210-213.
74. Swartz R.D., Messana J.M. Simultaneous catheter removal and replacement in peritoneal dialysis infections: update and current recommendations. Adv Perit Dial 1999, 15:205-208.
75. Chow K.M., Szeto C.C., Cheung K.K., et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis. Clin J Am Soc Nephrol 2006, 1:768-773.
76. Kwan T.H., Tong M.K., Siu Y.P., et al. Ultrasonography in the management of exit site infections in peritoneal dialysis patients. Nephrology (Carlton) 2004, 9:348-352.
77. Szeto C.C., Kwan B.C., Chow K.M., et al. Recurrent and relapsing peritonitis: causative organisms and response to treatment. Am J Kidney Dis 2009, 54:702-710.
78. Aykut S., Caner C., Ozkan G., et al. Mupirocin application at the exit site in peritoneal dialysis patients: five years of experience. Ren Fail 2010, 32:356-361.
79. Crabtree J.H., Burchette R.J., Siddiqi R.A., et al. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003, 23:368-374.
80. Prabhu M.V., Subhramanyam S.V., Gandhe S., et al. Prophylaxis against fungal peritonitis in CAPD-a single center experience with low-dose fluconazole. Ren Fail 2010, 32:802-805.